News
AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...
AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and ...
Zacks Investment Research on MSN1h
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback